Fluicell AB (FLUI) AI Stock Analysis

0 Followers

Fluicell AB

(Nasdaq OMX AB:FLUI)

Select Model

Rating:67Neutral

Price Target:SEK 31.00▲(8.39% Upside)

Action:downgraded

Date:09/11/26

Strong financial turnaround via revenue growth, profitability and low-leverage balance sheet is the primary driver. Supportive technical trend from price above moving averages and fair P/E valuation provide additional lift.

Positive Factors

Revenue and Profitability InflectionThe strong TTM revenue increase alongside positive EBIT and net income marks a meaningful operating inflection. If growth continues, expanding revenue can improve fixed-cost absorption and provide a more durable earnings base than the company’s prior loss-making periods.

Negative Factors

Negative Cash GenerationThe company is not yet self-funding despite reporting positive net income. Negative operating cash flow and materially negative free cash flow can require continued financing, limiting flexibility and making execution of growth plans more dependent on external capital.

Fluicell AB (FLUI) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 37.78M
Dividend Yield: ―
Average Volume (3M): 5,097
Price to Earnings (P/E): 14.0
Beta (1Y): 1.08
Revenue Growth: 837.37%
EPS Growth: ―
Country: Sweden
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Fluicell AB Business Overview & Revenue Model

Company Description

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic sys...

How the Company Makes Money

Fluicell makes money primarily by selling life-science research products and related services built around its single-cell microfluidics technology. Key revenue streams typically include: (1) Product sales of instruments/platforms (e.g., microfluidic...

Fluicell AB Financial Statement Overview

Summary

TTM results show strong revenue growth to 19.86M and positive net income with 91.6% gross margins, backed by solid low-debt balance sheet and positive ROE, though offset by ongoing negative cash flows and historical volatility.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.86M	6.00M	1.86M	3.34M	3.25M	2.60M
Gross Profit	18.20M	-8.69M	3.76M	1.74M	2.59M	1.89M
EBITDA	2.08M	-8.31M	-14.99M	-25.91M	-20.89M	-21.08M
Net Income	2.80M	-8.33M	-15.51M	-26.55M	-21.49M	-21.72M
Balance Sheet
Total Assets	25.01M	18.48M	25.51M	9.34M	31.77M	26.98M
Cash, Cash Equivalents and Short-Term Investments	30.00K	2.26M	15.92M	2.76M	24.46M	20.69M
Total Debt	2.00M	0	0	0	0	0
Total Liabilities	8.54M	7.57M	6.27M	8.91M	8.32M	7.87M
Stockholders Equity	16.47M	10.90M	19.23M	425.00K	23.45M	19.11M
Cash Flow
Free Cash Flow	-4.08M	-13.61M	-15.67M	-27.23M	-22.18M	-19.41M
Operating Cash Flow	-116.00K	-4.95M	-15.67M	-27.23M	-21.04M	-18.64M
Investing Cash Flow	-6.32M	-8.67M	-3.49M	0	-1.14M	-772.00K
Financing Cash Flow	2.00M	0	32.32M	5.53M	25.94M	21.31M

Fluicell AB Technical Analysis

Technical Analysis SentimentPositive

Last Price28.60

Price Trends

50DMA29.17Negative

100DMA30.50Negative

200DMA25.46Positive

Market Momentum

MACD-0.37Negative

RSI53.37Neutral

STOCH75.14Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUI, the sentiment is Positive. The current price of 28.60 is above the 20-day moving average (MA) of 27.48, below the 50-day MA of 29.17, and above the 200-day MA of 25.46, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 53.37 is Neutral, neither overbought nor oversold. The STOCH value of 75.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:FLUI.

Fluicell AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:FLUI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:FLUI	67Neutral	SEK 37.78M	13.99	21.37%	―	837.37%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:NXTCL	46Neutral	SEK 32.36M	-0.65	-81.23%	―	-4.02%	35.86%
SE:XINT	46Neutral	SEK 120.58M	-2.39	245.07%	―	-38.46%	9.02%
SE:BIOVIC.B	41Neutral	SEK 89.52M	-1.30	-75.51%	―	56.06%	63.95%
SE:FLUO	40Underperform	SEK 480.67M	-6.51	―	―	―	-23.57%

* Healthcare Sector Average

Performance Comparison

SE:FLUI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:FLUI	Fluicell AB	28.60	15.60	120.00%
SE:XINT	Xintela AB	0.14	-0.13	-47.96%
SE:BIOVIC.B	Biovica International AB Class B	0.32	-0.23	-41.30%
SE:NXTCL	NextCell Pharma AB	0.25	-0.55	-68.77%
SE:BIOWKS	Bio-Works Technologies AB	3.02	0.50	19.84%
SE:FLUO	FluoGuide A/S	28.90	-13.80	-32.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 11, 2026

Fluicell AB AI Stock Analysis